FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

Advocacy > Issues > Population-Wide BRCA Testing

| More


FORCE joined nearly 100 patient advocacy orgs in expressing concern about allowing Medicare Advantage plans to use step therapy. Read letter...

We joined in a letter encouraging the House Ways and Means Committee to make the 7.5% medical expense deduction permanent.

We sent a letter to Senator Collins (R-ME) seeking her leadership on national oral parity legislation

FORCE signed on to a coalition letter urging the Senate to maintain the allowed medical expense deduction at 7.5% of one's adjusted gross income.

This week, the House of Representative passed the Palliative Care and Hospice Education and Training Act to improve health professional training in palliative care. Read Bill...

Population-Wide BRCA Testing

Genetic Testing & Counseling


In 2014, Dr. Mary-Claire King, whose research led to the discovery of the BRCA1 gene associated with hereditary breast cancer and ovarian cancer, proposed that genetic testing for the BRCA1 and BRCA2 gene mutations become routine for all U.S. women over age 30. Among other things, King cited an Israeli study which revealed that Ashkenazi Jewish women with no family history of cancer—but who tested positive for a BRCA genetic mutation—have high rates of breast and ovarian cancer. 

Demonstration studies in the Ashkenazi Jewish population have shown that screening for the three BRCA founder mutations may be cost-effective and identifies carriers who would not have been suspected on the basis of their family cancer history. However, applying this to the broader, more diverse U.S. population may not yield the same results.

FORCE continues to consult with its scientific advisory board and other experts to evaluate these proposed changes and their implications on health care practice.

Search Policy Issues by Keyword

FORCE:Facing Our Risk of Cancer Empowered